Cargando…

Analysis of Adverse Effects of COVID-19 Vaccines in Spain following Booster Dose

The present study evaluates the adverse effects of three vaccines: AstraZeneca (Vaxzevria), Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) according to the dose. From 733 participants collected, the vaccine schedule was as follows: 330 (45%) received a double dose of the AstraZeneca vaccine, 382...

Descripción completa

Detalles Bibliográficos
Autores principales: Ríos, Esther, Medrano, Sara, Martínez, Mercedes, Novella, Consuelo, Marcos, Esther, Fernández, Jose J., Delgado-Iribarren, Alberto, Culebras, Esther
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504129/
https://www.ncbi.nlm.nih.gov/pubmed/36146475
http://dx.doi.org/10.3390/vaccines10091397
_version_ 1784796138298146816
author Ríos, Esther
Medrano, Sara
Martínez, Mercedes
Novella, Consuelo
Marcos, Esther
Fernández, Jose J.
Delgado-Iribarren, Alberto
Culebras, Esther
author_facet Ríos, Esther
Medrano, Sara
Martínez, Mercedes
Novella, Consuelo
Marcos, Esther
Fernández, Jose J.
Delgado-Iribarren, Alberto
Culebras, Esther
author_sort Ríos, Esther
collection PubMed
description The present study evaluates the adverse effects of three vaccines: AstraZeneca (Vaxzevria), Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) according to the dose. From 733 participants collected, the vaccine schedule was as follows: 330 (45%) received a double dose of the AstraZeneca vaccine, 382 (52.1%) received a double dose of Pfizer, 18 (2.5%) received a heterologous prime boost and 3 (0.4%) received a single dose. Pfizer and Moderna vaccines were administered as a third dose in 70 and 121 individuals, respectively. Local and systemic reactions observed in the three vaccines were mild to moderate in severity. Only one AstraZeneca recipient (0.3%) presented a serious adverse effect: blurred vision. Adverse events were more frequent after the first dose of AstraZeneca and after the second dose of Pfizer. As the third dose, Moderna causes more adverse effects than Pfizer regardless of the type of vaccine previously administered, whereas the reactogenicity of a third dose of Pfizer is slightly higher in the group previously vaccinated with Pfizer than in that group with AstraZeneca. In short, secondary effects of the third dose of COVID-19 vaccines were similar to those after dose 2, but their frequency depends on the type of vaccine and the combinations of vaccines.
format Online
Article
Text
id pubmed-9504129
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-95041292022-09-24 Analysis of Adverse Effects of COVID-19 Vaccines in Spain following Booster Dose Ríos, Esther Medrano, Sara Martínez, Mercedes Novella, Consuelo Marcos, Esther Fernández, Jose J. Delgado-Iribarren, Alberto Culebras, Esther Vaccines (Basel) Article The present study evaluates the adverse effects of three vaccines: AstraZeneca (Vaxzevria), Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax) according to the dose. From 733 participants collected, the vaccine schedule was as follows: 330 (45%) received a double dose of the AstraZeneca vaccine, 382 (52.1%) received a double dose of Pfizer, 18 (2.5%) received a heterologous prime boost and 3 (0.4%) received a single dose. Pfizer and Moderna vaccines were administered as a third dose in 70 and 121 individuals, respectively. Local and systemic reactions observed in the three vaccines were mild to moderate in severity. Only one AstraZeneca recipient (0.3%) presented a serious adverse effect: blurred vision. Adverse events were more frequent after the first dose of AstraZeneca and after the second dose of Pfizer. As the third dose, Moderna causes more adverse effects than Pfizer regardless of the type of vaccine previously administered, whereas the reactogenicity of a third dose of Pfizer is slightly higher in the group previously vaccinated with Pfizer than in that group with AstraZeneca. In short, secondary effects of the third dose of COVID-19 vaccines were similar to those after dose 2, but their frequency depends on the type of vaccine and the combinations of vaccines. MDPI 2022-08-25 /pmc/articles/PMC9504129/ /pubmed/36146475 http://dx.doi.org/10.3390/vaccines10091397 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ríos, Esther
Medrano, Sara
Martínez, Mercedes
Novella, Consuelo
Marcos, Esther
Fernández, Jose J.
Delgado-Iribarren, Alberto
Culebras, Esther
Analysis of Adverse Effects of COVID-19 Vaccines in Spain following Booster Dose
title Analysis of Adverse Effects of COVID-19 Vaccines in Spain following Booster Dose
title_full Analysis of Adverse Effects of COVID-19 Vaccines in Spain following Booster Dose
title_fullStr Analysis of Adverse Effects of COVID-19 Vaccines in Spain following Booster Dose
title_full_unstemmed Analysis of Adverse Effects of COVID-19 Vaccines in Spain following Booster Dose
title_short Analysis of Adverse Effects of COVID-19 Vaccines in Spain following Booster Dose
title_sort analysis of adverse effects of covid-19 vaccines in spain following booster dose
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9504129/
https://www.ncbi.nlm.nih.gov/pubmed/36146475
http://dx.doi.org/10.3390/vaccines10091397
work_keys_str_mv AT riosesther analysisofadverseeffectsofcovid19vaccinesinspainfollowingboosterdose
AT medranosara analysisofadverseeffectsofcovid19vaccinesinspainfollowingboosterdose
AT martinezmercedes analysisofadverseeffectsofcovid19vaccinesinspainfollowingboosterdose
AT novellaconsuelo analysisofadverseeffectsofcovid19vaccinesinspainfollowingboosterdose
AT marcosesther analysisofadverseeffectsofcovid19vaccinesinspainfollowingboosterdose
AT fernandezjosej analysisofadverseeffectsofcovid19vaccinesinspainfollowingboosterdose
AT delgadoiribarrenalberto analysisofadverseeffectsofcovid19vaccinesinspainfollowingboosterdose
AT culebrasesther analysisofadverseeffectsofcovid19vaccinesinspainfollowingboosterdose